Skip to main content
. 2020 Sep 28;12:83. doi: 10.1186/s13073-020-00780-z

Fig. 2.

Fig. 2

Synergistic therapeutic effect of combination treatments with MMP2/9 inhibitor, SB-3CT, and anti-PD-1. Images of a B16F10 tumor and b LLC tumor, collected from the combination strategies (control: isotype; PD1 inhibition: anti-PD1; MMP2/9 inhibition: SB-3CT; combination treatment: anti-PD-1+SB-3CT). The B16F10 tumor was captured at the ninth days, and the LLC tumor was captured at the fifth days after treatment. Tumor volumes of c B16F10 and d LLC tumor-bearing C57/BL6 mice treated with isotype, SB-3CT, anti-PD-1, or combination strategy. Kaplan–Meier survival analysis of e B16F10 or f LLC tumor-bearing C57/BL6 mice treated with isotype, SB-3CT, anti-PD-1, or combination strategy. Body weight of g B16F10 and h LLC tumor-bearing C57/BL6 mice treated with isotype, SB-3CT, anti-PD-1, or combination strategy. Sample size per group in one experiment is 5. Error bars represent s.d. of individual mice per group in one experiment. NS, p > 0.05, *p < 0.05, **p < 0.01, and ***p < 0.001, as determined by c, d two-way ANOVA, e, f two-sided log-rank test, and g, h one-way ANOVA